HomeAI · summaries
Storia in 4 fonti
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a…
- ·
statnews.com
Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene-editing companies against each other.
